Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir

Table 2

Proportion of women achieving an HIV viral load <50  copies/mL by treatment regimen at time of delivery.

	*	HIV viral load <50  copies/mL; %; (95% CI)
All regimens	122	80.3%; (72.1–86.6%)
ATV 300/R throughout**	101	83.2%; (74.3–89.4%)
ATV 400/R escalated***	11	72.7%; (33.5–93.4%)
ATV 400 throughout^†	7	50%; (11.0–89.0%)
ATV >400^‡	2	100%; (15.8–100%)
ATV 400 (reduced to 300/R)	1	100%; (2.5–100%)

: number of pregnancies in which women were taking the specified regimen at the time of delivery.
**ATV 300/R throughout: women were prescribed atazanavir 300 mg/ritonavir 100 mg at all times when an atazanavir based regimen was prescribed in the recorded pregnancy.
***ATV 400/R escalated: women prescribed atazanavir 300 mg/ritonavir 100 mg initially; then dose increased to atazanavir 400 mg/ritonavir 100 mg in the third trimester.
^†ATV 400 throughout: women prescribed atazanavir 400 mg without ritonavir throughout pregnancy.
^‡ATV >400 two pregnancies, both occurring in the same woman, where a dose of atazanavir >400 mg was prescribed without ritonavir boosting.
ATV 400 (reduced to 300/R): women prescribed atazanavir 400 mg without ritonavir at the start of pregnancy which was converted to atazanavir 300 mg/ritonavir 100 mg.